Th e goal of our project has been to establish human organoid/enteroid cultures as a preclinical model to study the pathophysiology of non-infl ammatory (small intestinal) diarrheas and infl ammatory diarrhea models as well as to develop drug therapy. Th e rate-limiting step in translational research is often the absence of reliable preclinical models that adequately refl ect relevant human physiology and disease pathophysiology. Moreover, drug development based on in vitro cell culture and/or animal models often fails in clinical trials due to ineff ectiveness and/or signifi cant side eff ects. Since detailed studies of the contributions of specifi c transport proteins to normal intestinal water and electrolyte homeostasis have not been accomplished in human intestine, one cause of these failures that must be considered is that diff erences may exist between humans and other model systems in the expression, localization and/or regulation of proteins that are important for normal intestinal transport or that become abnormal as part of the pathophysiology of diarrhea. Th ere is thus an urgent need to develop and validate novel preclinical models of human diseases in general.
Introduction
Th e goal of our project has been to establish human organoid/enteroid cultures as a preclinical model to study the pathophysiology of non-infl ammatory (small intestinal) diarrheas and infl ammatory diarrhea models as well as to develop drug therapy. Th e rate-limiting step in translational research is often the absence of reliable preclinical models that adequately refl ect relevant human physiology and disease pathophysiology. Moreover, drug development based on in vitro cell culture and/or animal models often fails in clinical trials due to ineff ectiveness and/or signifi cant side eff ects. Since detailed studies of the contributions of specifi c transport proteins to normal intestinal water and electrolyte homeostasis have not been accomplished in human intestine, one cause of these failures that must be considered is that diff erences may exist between humans and other model systems in the expression, localization and/or regulation of proteins that are important for normal intestinal transport or that become abnormal as part of the pathophysiology of diarrhea. Th ere is thus an urgent need to develop and validate novel preclinical models of human diseases in general.
Th is need is particularly true in the fi eld of human diarrheal diseases, which cause ~4% of all deaths worldwide, including 1.2 million deaths in children per year, and are a leading cause of death in the aged population in the USA [1] . Th e morbidity/mortality caused by diarrhea is due to abnormal regulation of ion and water transport across the intestinal epithelium leading to signifi cant dehydration. Th e goal of therapy is to rehydrate the patient either using transport processes not aff ected by the diarrheal disease (the concept on which oral rehydration solutions were developed) or by restoring normal intestinal electrolyte transport. In all diarrheal diseases there is reduced Na + absorption primarily due to inhibition of the brush border Na + /H + exchanger NHE3 and perhaps the Cl -/HCO 3 -exchanger DRA, while in enterotoxigenic diarrheas there is additional stimulation of anion secretion via the cystic fi brosis transmembrane conductance regulator (CFTR) [2, 3] . Unfortunately, over the past 35 years the approaches to correct this abnormal intestinal ion transport in diarrhea have failed to produce any signifi cant drug for treating diarrhea to supplement the use of oral rehydration solution-based therapy, which is currently used in only ~33% of children with severe diarrhea in developing countries [1] .
Approach
A human intestinal model that duplicates normal physiologic salt and water transport and is reproducible and readily available is needed as part of the strategy for drug
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Components of the microbiome that are present luminally also are likely to infl uence this regulation. Transport proteins are attractive drug targets that likely require consideration of developmental stages, so a system to duplicate diff erences in transport protein expression across infant, adult, and aged populations would be useful. Another potential barrier for drug development in diarrheal diseases relates to the presence of polymorphisms, epigenetic modifi cations and diff erences in drug metabolism in individual patients, an area that has led to the concept of personalized medicine. Recent progress in the identifi cation and isolation of human intestinal epithelial stem cells has led to the creation ex vivo of three-dimensional small intestinal epithelial functional units called intestinal organoids and enteroids that include the entire villus-crypt axis and all epithelial cell types normally present. Two techniques using human intestinal stem cells have been reported [5] [6] [7] . One starts with human pluripotent stem cells (H9 or others; WiCell International Stem Cell Bank, Madison, WI, USA) that diff eren tiate into organoid cultures which contain multiple cell types, including enterocytes, goblet cells, enteroendo crine cells, Paneth cells and mesenchymal cell popu lations. Th e second technique starts with whole intestinal crypts isolated from adult human intestinal tissue (surgery or biopsies) and includes only epithelial cells, Paneth cells, goblet cells and enteroendocrine cells (ex pres sion of M cells requires additional culture conditions [8] ) but does not contain mesenchymal elements. Th e develop ment of these enteroids was pioneered by the ground breaking studies of Hans Clevers and his coworkers in Utrecht, the Netherlands, who identifi ed the intestinal stem cell as one expressing Lgr5 [9] and established the conditions needed to initiate small and large intestinal enteroid growth and long-term culture, as well as the conditions to induce diff erentiation [5, 10] . Th e approaches to grow enteroids are very recent and modifi cations have been reported [11] [12] [13] .
Using Clevers' methods, we have been establishing human enteroids as a model to understand the physiologic control of intestinal water and electrolyte transport, including changes that occur in digestion and become exaggerated in diarrheal diseases. Recently, Dekkers and colleagues demonstrated in human enteroids derived from rectal biopsies that forskolin-induced luminal dilation can serve as a functional assay to measure CFTR function [14] . Models presently established in our labora tories include enteroids from the human duodenum, jejunum, ileum and proximal colon. Studies have been initiated to characterize them as regards: polarity; expression of transport proteins involved in intestinal Na + absorption and Cl -secretion, including expression along the horizontal axis of the intestine and along the villus-crypt axes under normal conditions and in disease; comparison with intact human tissue concerning locali zation of transport proteins and polarization markers along vertical and horizontal axes of the intestine; ability to freeze these ex vivo preparations as well as to re-establish the cultures from the frozen specimens; maintenance of functional characteristics over multiple passages; interaction with luminal bacteria and viruses as components of the human microbiome; and genetic and epigenetic diversity.
Th e enteroids were obtained from endoscopic biopsies from subjects felt to have no organic intestinal pathology after endoscopy and surgical specimens that otherwise would have been discarded, which is enabling establishment of an enteroid bank. Th is will facilitate consideration of biologic diversity among human subjects in terms of all parameters to be studied. Th ese enteroids are polarized, based on localization of known apical (villin), basolateral membrane (Na + /K + -ATPase) markers, and tight junction morphology using immunofl uorescence and transmission electron microscopy ( Figure 1) . Th e enteroids express transport proteins that take part in Na + absorption and anion secretion similar to normal human intestine along the horizontal and vertical axes of the intestine. NHE3, DRA, SGLT1 and CFTR are expressed apically, while Na + /K + -ATPase and NKCC1 are localized to the basolateral membrane; SGLT1 is present in the duodenum and jejunum, minimally expressed in the ileum, and absent in the proximal colon. Th e enteroids also express Ca 2+ -activated Cl -channels and K + channels. Although enteroids do not form fl at monolayers in this particular culture system, ion transport activity can be measured in intact three-dimensional cultures. Regulation of Na + absorption and Cl -secretion in the enteroids occur as in human intestine, with forskolin inhibiting NHE3 and stimulating Cl -secretion by activating CFTR (Figure 2) . Th is regulation mimics what occurs in the human jejunum in the early postprandial period.
Besides their relevance for understanding human intestinal physiology, the enteroids serve as an excellent model of human enteric infections. We previously showed that organoids are susceptible to infection with rotavirus [15] and we have now evaluated the use of enteroids to study rotavirus infectivity and replication. Jejunal enteroids established from tissues of patients undergoing bariatric surgery can support rotavirus replication, as confi rmed by detection of nonstructural viral proteins by immunofl uorescence (Figure 3a) and increased levels of viral RNA by quantitative RT-PCR (Figure 3b) . Th e nonstructural viral proteins, NSP4 and NSP5, show the expected punctate staining patterns, representing viroplasms, the sites of virus replication and particle assembly. Th ese results demonstrate the ability to com pare rotavirus infection and replication in organoids and enteroids, and demonstrate that the enteroids may be useful to study pathogenesis of multiple enteric pathogens.
Conclusion
Th ese studies have been initiated recently, and while enteroid culture and initial functional studies have been achieved, further goals in the study of pathophysiology of diarrhea must consider two factors. First, one must consider the pathogenesis of diarrhea in neural regulation of intestinal Na + absorption and Cl -secretion, given that ~50% of several severe diarrheas (cholera toxin-induced and rotavirus diarrhea) are neurally mediated [16, 17] . Th e second factor to consider is the role of diff erentiation of the enteroids in the expression level and localization of transport proteins and their physiologic and pathophysio logic regulation. Future studies will also evaluate changes in expression of key transport proteins following infection as well as establishing methods to evaluate drug eff ects on normal and infected cultures, including those grown as monolayers [18] .
